Your session is about to expire
← Back to Search
Gonadotropin-Releasing Hormone (GnRH) Antagonist
Relugolix Combination Therapy for Birth Control (SERENE Trial)
Phase 3
Waitlist Available
Research Sponsored by Sumitomo Pharma Switzerland GmbH
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Is a premenopausal woman, 18 to 50 years of age.
Is at risk of pregnancy (that is, having heterosexual intercourse at least once per month) and is seeking contraception.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months on-treatment or eot
Awards & highlights
SERENE Trial Summary
This trial will test how well a combination of drugs called relugolix works as a contraceptive in women.
Who is the study for?
This trial is for premenopausal women aged 18-50 who are at risk of pregnancy and seeking contraception. Participants must be willing to use the study drug as their only birth control method for over a year. They should have either endometriosis confirmed by surgery or severe menstrual pain, or uterine fibroids diagnosed via ultrasound with heavy bleeding.Check my eligibility
What is being tested?
The trial is testing Relugolix Combination Therapy's ability to prevent pregnancy in women with uterine fibroids or endometriosis. It will measure how effective this therapy is when used as the sole contraceptive method across multiple menstrual cycles.See study design
What are the potential side effects?
While not explicitly listed here, potential side effects may include hormonal changes typical of contraceptives such as mood swings, weight gain, headaches, nausea, and possibly specific effects related to Relugolix like bone density reduction.
SERENE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am a woman aged 18 to 50 and have not gone through menopause.
Select...
I am at risk of pregnancy and seeking contraception.
Select...
You have menstrual cycles that are regular, occurring every 21 to 35 days.
Select...
I have uterine fibroids diagnosed by ultrasound in the last 2 years and they cause me heavy menstrual bleeding.
Select...
I have been diagnosed with endometriosis, confirmed by surgery or biopsy, and I experience significant pain.
Select...
You must use the study treatment as your only form of birth control for 13 months and cannot use any other contraception methods like condoms.
Select...
This is not an exclusion criterion, but rather a question to gather information about the participant's height.
Select...
What is your weight in pounds?
SERENE Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months on-treatment or eot
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months on-treatment or eot
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Contraceptive Efficacy of Relugolix Combination Therapy as Assessed by the At-Risk Pearl Index (PI)
Secondary outcome measures
Contraceptive Efficacy of Relugolix Combination Therapy as Assessed by the Cumulative 1-Year Pregnancy Rates
Contraceptive Efficacy of Relugolix Combination Therapy as Assessed by the Gross PI
Combined Modality Therapy
+5 moreSERENE Trial Design
1Treatment groups
Experimental Treatment
Group I: Relugolix/E2/NETAExperimental Treatment1 Intervention
Participants will receive relugolix combination therapy for 1 year (13 consecutive 28-day treatment cycles).
Find a Location
Who is running the clinical trial?
Sumitomo Pharma Switzerland GmbHLead Sponsor
16 Previous Clinical Trials
4,795 Total Patients Enrolled
Myovant Sciences GmbHLead Sponsor
22 Previous Clinical Trials
11,470 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have menstrual cycles that are regular, occurring every 21 to 35 days.I have uterine fibroids diagnosed by ultrasound in the last 2 years and they cause me heavy menstrual bleeding.I have been diagnosed with endometriosis, confirmed by surgery or biopsy, and I experience significant pain.You must use the study treatment as your only form of birth control for 13 months and cannot use any other contraception methods like condoms.I am at risk of pregnancy and seeking contraception.I am a woman aged 18 to 50 and have not gone through menopause.This is not an exclusion criterion, but rather a question to gather information about the participant's height.What is your weight in pounds?
Research Study Groups:
This trial has the following groups:- Group 1: Relugolix/E2/NETA
Awards:
This trial has 2 awards, including:- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger